Germany's Direvo Biotech, a protein engineering company, has raised $16.8 million in its third round. Part of that money is being earmarked for its collaboration and research programs in therapeutic proteases and antibodies. A big group of investors participated in the round, including Danisco Venture A/S, Copenhagen, S-Equity Partner, Cologne, Mulligan BioCapital, Hamburg and funds managed by New York based Signet Healthcare Partners, as well as private investors such as Nobel laureate Prof. Manfred Eigen.
- see this release for more info
ALSO: Ikonisys has raised $30 million to advance its work in diagnostics. Release
Read more on: Venture capital news